

**Table S4 Clinicopathologic characteristics of prostate cancer patients**

**A. Clinicopathologic characteristics of training cohort of PCa patients used for ex-miR-1246 profiling**

<b>Characteristic</b>	<b>Cohort 1 (N=44)</b>	<b>Cohort 2 (N=25*)</b>
	<b>N (%)</b>	<b>N (%)</b>
<b>Age, Years</b>		
Mean	64.3	61.2
Median	65.5	62
Range	46-78	42-76
<b>T-stage</b>		
pT2	4 (9)	16 (64)
pT3	3 (7)	8 (32)
pT4	36 (84)	-
<b>Gleason Score</b>		
4-6	-	1 (4)
7 (3+4)	12 (28)	18 (72)
7 (4+3)	9 (21)	2 (8)
8-10	19 (44)	4 (16)
<b>PSA</b>		
Median	7.05 (2.6-54)	5.6 (3-52)
<b>N-stage</b>		
N0/NX	17 (39)	25 (100)
N1	26 (59)	-
<b>M-stage</b>		
M0/MX	44 (100)	25 (100)
M1	-	-

**Pathological diagnosis**

Adenocarcinoma

44 (100)

25 (100)

\* Pathological stage and N-stage unknown for 1 case, Gleason score for 4 cases, PSA for 3 cases

**B. Clinicopathologic characteristics of validation cohort of PCa patients used for ex-miR-1246 profiling (N=43)**

<b>Characteristic</b>	<b>N(%)</b>
<b>Age, Years</b>	
Mean	66
Median	65
Range	48-80
<b>Gleason Score</b>	
4-6	4 (9)
7 (3+4)	9 (21)
7 (4+3)	10 (23)
8-10	16 (37)
<b>PSA</b>	
Median	13 (3.3-512.6)
<b>M-stage</b>	
M1	43 (100)
<b>Pathological diagnosis</b>	
Adenocarcinoma	43 (100)

\* Age unknown for 1 case, Gleason score for 4 cases, PSA for 8 cases

**C. Clinicopathologic characteristics of prostate cancer patients used for miR-1246 profiling in clinical tissues**

<b>Characteristic</b>	<b>N (%)</b>
<b>Age, Years</b>	
Mean	63.9
Median	63.5
Range	52-76
<b>T-stage</b>	
pT2 or lower	16 (44)
pT3	16 (44)
pT4	3 (8)
<b>Gleason Score</b>	
4-6	8 (22)
7 (3+4)	14 (39)
7 (4+3)	6 (17)
8-10	6 (17)
<b>PSA</b>	
Median	7.55 (<0.1-61.1)
<b>N-stage</b>	
N0/NX	3 (8)
N1	33 (92)
<b>M-stage</b>	
M0/MX	36 (100)
M1	-
<b>Pathological diagnosis</b>	
Adenocarcinoma	36 (100)

\* Pathological stage unknown for 1 case, Gleason score for 2 cases, PSA for 1 case